International Medical Research Frontier

Objective To study the clinical effect of methotrexate combined with tofacitinib in patients with refractory rheumatoid arthritis. Methods 300 patients with refractory rheumatoid arthritis who received treatment in our hospital were selected and divided into three groups: A, B and C according to different treatment plans. 100 patients were treated with leflunomide combined with methotrexate. The patients are group A, and 100 patients treated with Yisaipu combined with methotrexate are group B (the grouping here is different from the grouping in the following method, and the treatment plan of group A and B is different), and tofacitinib combined with methotrexate The 100 patients treated with pterin were group C. The drug treatment effects, regulatory T cells, T cells, B cells, inflammatory factors, bone destruction score, pain score, and adverse drug reactions were compared among the three groups of subjects before and after treatment. Results The total effective rate of drug treatment in group C was higher than that in group B, P<0.05 for the comparison of data between groups; CD4+, CD8+, CD4+/CD8+ values, inflammatory factors, bone destruction score, and pain score before and after treatment improved more than those in the control group. Data comparison between groups P<0.05. There was no significant difference in the above index data between group B and group A, P>0.05. Conclusion The treatment of patients with refractory rheumatoid arthritis with methotrexate combined with tofacitinib can significantly improve regulatory T cells, T cells, B cells, inflammatory factors, and bone destruction, rapidly reduce pain, and reduce Adverse drug reactions increase the overall effective rate of treatment.

Refractory rheumatoid arthritis; Methotrexate; tofacitinib; Bone destruction